Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothiol that plays a central role in health and disease.   N30 Pharma's research efforts, along with the published literature, strongly support the concept that many aspects of asthma, COPD, IBD and cardiovascular diseases can be attenuated by inhibiting GSNOR.  N30 Pharma's discovery efforts have produced advanced development candidates that show efficacy with remarkable specificity when administered orally, intravenously and by inhalation in pre-clinical models of asthma, COPD, IBD, and cardiovascular disease.  N30 Pharma has also developed a  monoclonal antibody to GSNOR which may be useful in identifying patient subsets that are more likely to respond to GSNOR inhibition.

About N30 PharmaN30 Pharma is a privately held biopharmaceutical company headquartered in Boulder, Colorado.  N30 Pharma focuses on the discovery and development of proprietary drugs that provide therapeutic advantage over current treatment for major human diseases such as asthma, COPD and IBD. The Company's strategy is to focus upon discovery research and early-stage clinical development, and then establish one or more partnerships with leading pharmaceutical companies to accelerate advancement of its lead clinical candidates.N30 ContactsEmail: info@N30Pharma.comJanice Troha

Charles Scoggin, MDVP, Product Development and Regulatory Affairs

CEO(720) 945 7714

(720) 945 7721
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical ... knowledge and skills while treating their patients. ... hands-on experience without involving patients. Simulation provides ... Clinicians can carry out procedures, refine techniques ... risk. Integration of new technology, such as ...
(Date:9/5/2017)... announced another milestone in their continued growth and success of the company.  Xyntek ... customer engagements regionally.  ... located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support ... In addition to Xyntek,s ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... ... Device Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification      , ... Manufacturers must prove that their equipment, operations and processes all work the ...
(Date:9/26/2017)... ... September 26, 2017 , ... Dr. Kovatis, is a Hospital ... Ankle, and Foot Section of the Department of Orthopedic Surgery at Hackensack University ... Hackensack UMC performing total ankle replacements. Because of this, Dr. Kovatis is often ...
(Date:9/26/2017)... ... 26, 2017 , ... DETECTO has been awarded ... 2017, the new agreement allows Premier members, at their discretion, to take advantage ... is pleased to renew our agreement with Premier to be able to supply ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength ... overcoming obstacles. “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation ... from Fort Hays Sate University, who has worked at a local mental health center ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a ... draw readers back, and help them relive their own youth. “Childhood Memories of a ... operator in the US Navy for nine years. He received his BS from ...
Breaking Medicine News(10 mins):